Effect of resveratrol on scopolamine-induced cognitive impairment in mice.
BACKGROUND
Resveratrol (3,4',5-trihydroxystilbene) is a naturally occurring compound found in grapes, wine, peanuts and cranberries. Recently, in vitro and cell culture studies have reported beneficial effects of resveratrol in the neurodegenerative process in Alzheimer's disease (AD). However, in vivo effect of resveratrol in models of learning and memory is not yet evaluated. The present study was performed to examine the effect of resveratrol on cognitive impairment induced by scopolamine, a muscarinic antagonist, in mice.


METHODS
Scopolamine was administered in a dose of 1 mg/kg intraperitoneally (ip). Cognitive functions were assessed using transfer latency (TL) on elevated plus maze, step-down latency (SDL) on a passive avoidance apparatus and escape latency (EL) in Morris water maze test.


RESULTS
Scopolamine produced significant prolongation of TL, reduction in SDL as well as EL showing cognitive impairment in mice. Pre-treatment with resveratrol (10 mg/kg and 20 mg/kg, ip) for 21 days showed no difference in TL, SDL and EL.


CONCLUSIONS
Resveratrol treatment does not reverse scopolamine-induced deficit in cognitive functions in mice.
Department of Pharmacology, University College of Medical Sciences and GTB Hospital, New Delhi 110095, India. drrachna1@rediffmail.com
Rachna
R
Gupta
Lalit K
LK
Gupta
Pramod K
PK
Mediratta
Swapan K
SK
Bhattacharya
D000818:Animals; D001362:Avoidance Learning / Q000187:drug effects; D001522:Behavior, Animal / Q000187:drug effects*; D003072:Cognition Disorders / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D007274:Injections, Intraperitoneal; D018782:Maze Learning / Q000187:drug effects; D008569:Memory Disorders / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D018727:Muscarinic Antagonists; D018696:Neuroprotective Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D011930:Reaction Time / Q000187:drug effects; D000077185:Resveratrol; D012601:Scopolamine; D013267:Stilbenes / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D018727:Muscarinic Antagonists; D018696:Neuroprotective Agents; D013267:Stilbenes; D012601:Scopolamine; D000077185:Resveratrol